Upper Motor Neurons in Primary Lateral Sclerosis

Upper Motor Neurons in Primary Lateral Sclerosis

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Upper Motor Neurons in Primary Lateral Sclerosis</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Upper Motor Neurons in Primary Lateral Sclerosis</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Upper Motor Neurons in Primary Lateral Sclerosis

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Upper Motor Neurons in Primary Lateral Sclerosis</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Upper Motor Neurons in Primary Lateral Sclerosis</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Primary Lateral Sclerosis (PLS) is a rare adult-onset neurodegenerative disorder characterized by selective degeneration of upper motor neurons (UMNs) — the corticospinal neurons that originate in the motor cortex and project to the spinal cord["@singer2007"]. Unlike amyotrophic lateral sclerosis (ALS), PLS predominantly affects UMNs with relative preservation of lower motor neurons, resulting in a clinical syndrome dominated by spasticity, hyperreflexia, and progressive motor impairment["@pradat2009"].

The disease typically presents in adults between 40 and 60 years of age and progresses over decades, distinguishing it from the more rapid course of ALS. Understanding the pathophysiology of UMN degeneration in PLS is critical for developing targeted therapeutic interventions and distinguishing PLS from related motor neuron disorders.

Clinical Presentation and Diagnostic Criteria

Core Clinical Features

The clinical manifestations of PLS reflect the selective loss of corticospinal tract function:

Spasticity: The hallmark symptom of PLS is progressive spasticity, typically beginning in the lower extremities and spreading proximally. Spasticity results from loss of cortical inhibition on spinal motor circuits, leading to velocity-dependent increase in muscle tone[@ferreira2019].

Hyperreflexia: Deep tendon reflexes are markedly increased, particularly at the knee and ankle. Pathological reflexes such as the Babinski sign (extensor plantar response) and Hoffmann sign are typically present.

Muscle weakness: Progressive weakness accompanies spasticity, affecting both proximal and distal muscle groups. Weakness is typically more severe in the lower extremities initially.

Pseudobulbar affect: Some patients develop emotional lability with uncontrolled crying or laughing, reflecting corticobulbar tract involvement.

Diagnostic Criteria

The clinical diagnosis of PLS requires:

The distinction between PLS and ALS remains challenging, as approximately 10-30% of patients initially diagnosed with PLS eventually develop lower motor neuron signs consistent with ALS[@zhang2021].

Neuropathology

Upper Motor Neuron Degeneration

The neuropathological hallmark of PLS is selective degeneration of corticospinal neurons:

Cellular changes: Betz cells — the giant pyramidal neurons in layer V of the primary motor cortex — undergo degeneration, accompanied by loss of smaller pyramidal neurons in the corticospinal tract[@turner2010]. Affected neurons show:

• Progressive cytoplasmic shrinkage
• Nuclear pyknosis
• Neurofibrillary tangle formation in some cases
• Vacuolization and mitochondrial abnormalities

Gliosis: Reactive astrogliosis accompanies neuronal loss, with proliferation of astrocytes in the motor cortex and along the corticospinal pathway.

Regional Distribution

The pattern of UMN loss in PLS shows some heterogeneity:

• Motor cortex: Predominant involvement of Betz cells in the precentral gyrus
• Corona radiata: Degeneration of descending corticospinal fibers
• Internal capsule: Loss of corticospinal tract integrity
• Brainstem: Variable involvement of corticobulbar fibers
• Spinal cord: Degeneration of lateral corticospinal tracts

Etiology and Risk Factors

Sporadic PLS

The majority of PLS cases are sporadic, with no clear inheritance pattern. The etiology remains poorly understood, but several mechanisms have been proposed:

• Excitotoxicity: Excessive glutamate signaling leading to excitotoxic neuronal death
• Oxidative stress: Accumulation of reactive oxygen species damaging neuronal components
• Mitochondrial dysfunction: Impaired energy metabolism in corticospinal neurons
• Protein aggregation: In some cases, TDP-43 pathology similar to ALS

Hereditary Forms

A small proportion of PLS cases demonstrate familial inheritance:

• Autosomal dominant: Several families show apparent autosomal dominant transmission
• SOD1 mutations: Rarely, SOD1 mutations typically associated with ALS can present as PLS
• TARDBP mutations: TARDBP (TDP-43) gene mutations have been reported in some PLS families
• C9orf72 expansions: Hexanucleotide repeat expansions in C9orf72, the most common genetic cause of ALS/FTD, have been identified in some PLS cases[@marsden2012]

Neuroimaging Findings

MRI Characteristics

Magnetic resonance imaging in PLS reveals:

Cortical atrophy: Focal atrophy of the precentral gyrus and adjacent motor cortex is common. This can be quantified using voxel-based morphometry.

Corticospinal tract abnormalities: T2 hyperintensity along the corticospinal pathway, particularly in the posterior limb of the internal capsule and brainstem, is a characteristic finding.

Advanced techniques:

• Diffusion tensor imaging (DTI) shows reduced fractional anisotropy in corticospinal tracts
• Proton magnetic resonance spectroscopy may reveal reduced N-acetylaspartate (neuronal marker)
• PET imaging with [11C]-(R)-PK11195 demonstrates microglial activation in motor cortex

Differential Diagnosis on Imaging

MRI helps distinguish PLS from:

• ALS: More prominent frontotemporal involvement in ALS
• Hereditary spastic paraplegia: Typically normal MRI or nonspecific changes
• Cerebral small vessel disease: White matter hyperintensities in different pattern

Electrophysiology

Motor Evoked Potentials

Transcranial magnetic stimulation (TMS) reveals:

Central motor conduction time: Prolonged central motor conduction time (CMCT), reflecting corticospinal tract dysfunction.

Motor threshold: Increased resting motor threshold in PLS patients, suggesting cortical hyperexcitability.

Motor-evoked potentials: Reduced amplitude and increased latency of motor-evoked potentials.

Needle Electromyography

Unlike ALS, needle EMG in PLS typically shows:

• Normal motor unit potentials in most muscles
• Absence of fibrillation potentials and positive sharp waves
• Minimal chronic neurogenic changes if present
• Normal recruitment patterns in early disease

Biomarkers

Neurofilament Markers

Neurofilament light chain (NfL) in cerebrospinal fluid and blood has emerged as a biomarker:

• Elevated NfL in PLS: Reflects ongoing axonal degeneration[@gethalany2018]
• Correlation with disease progression: Higher levels associated with faster progression
• Differentiation from ALS: NfL typically lower in PLS than ALS
• Prognostic value: Baseline NfL predicts rate of disease progression

Other Biomarkers

• Tau protein: Elevated in some PLS patients
• Beta-amyloid: May be abnormal in PLS with cognitive involvement
• Neuroimaging biomarkers: Cortical thickness, DTI metrics

Treatment Approaches

Symptomatic Management

Current treatments for PLS focus on symptom management:

Spasticity management:

• Baclofen: GABA(B) receptor agonist, reduces spasticity
• Tizanidine: Alpha-2 adrenergic agonist
• Benzodiazepines: Diazepam or clonazepam for severe spasticity
• Botulinum toxin injections: For focal spasticity

• Physical therapy: Maintains range of motion, prevents contractures
• Occupational therapy: Adaptive strategies for daily activities
• Assistive devices: Walkers, wheelchairs as disease progresses

Disease-Modifying Therapies

NP001: A phase 2 randomized controlled trial investigated NP001 (a macrophage migration inhibitory factor inhibitor) in PLS[@smith2020]. While the study did not meet its primary endpoint, subgroup analyses suggested potential benefit in patients with elevated inflammatory markers.

Riluzole: The only FDA-approved disease-modifying therapy for ALS has shown limited benefit in PLS. Some clinicians use it off-label, particularly in patients with rapid progression.

Future directions:

• Gene therapy targeting specific mutations
• Stem cell-based approaches to replace lost neurons
• Immunomodulatory therapies targeting neuroinflammation
• Neuroprotective agents to slow disease progression

Clinical Trials

Several clinical trials are ongoing or recently completed:

• NCT02045810: Phase 2 trial of NP001 (completed)
• NCT02326669: Lithium carbonate in PLS (completed)
• Various observational studies characterizing PLS natural history

Relationship to Other Motor Neuron Diseases

PLS vs. ALS

The relationship between PLS and ALS remains controversial:

Common features:

• Overlapping TDP-43 pathology in some cases
• Shared genetic risk factors (C9orf72, TARDBP)
• Similar clinical presentation initially

• PLS: Isolated UMN involvement, slower progression
• ALS: Combined UMN and LMN involvement, rapid progression
• PLS: Later onset, longer disease duration

PLS vs. Hereditary Spastic Paraplegia

Both conditions present with spasticity, but:

• HSP: Earlier onset, pure phenotype, genetic causes identified
• PLS: Adult onset, possibleUMN and cognitive involvement

PLS Variants

SeveralPLS variants are recognized:

• Adult-onset PLS: Most common form
• Juvenile-onset PLS: Rare, may have different etiology
• PLS with cognitive involvement: Some patients develop frontotemporal dysfunction

Cross-References and Related Topics

• [Primary Lateral Sclerosis](/diseases/primary-lateral-sclerosis) — Main disease page
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Related motor neuron disease
• [Motor Cortex](/brain-regions/motor-cortex) — Location of UMN cell bodies
• [Corticospinal Tract](/mechanisms/corticospinal-tract-pathway) — UMN axonal projections
• [Spasticity](/symptoms/spasticity) — Core symptom of PLS
• [Betz Cells](/cell-types/betz-cells) — Large pyramidal neurons in motor cortex
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — Protein pathology in ALS/PLS
• [Neurofilament Biomarkers](/mechanisms/neurofilament-biomarkers) — Disease biomarkers

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Upper Motor Neurons in Primary Lateral Sclerosis discovered through SciDEX knowledge graph analysis: